<DOC>
	<DOCNO>NCT01493856</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetic characteristic combination rosuvastatin CS-866 DWJ1276 alone .</brief_summary>
	<brief_title>A Clinical Trial Compare Safety Pharmacokinetic Characteristics Combination Rosuvastatin CS-866 DWJ1276</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Healthy adult male volunteer age 20 50 year 2 . A subject provide write informed consent participate study cooperative regard compliance study relate constraint 1 . A subject allergic history drug . 2 . A subject sign symptom previously diagnose disease liver , kidney , neurology , respiratory , endocrinology , hematology , cardiovascular , genitourinary , psychology , ophthalmic , dermatology gastrointestinal function significant diseases 3 . History suspicion current drug abuse 4 . A subject receive treatment list drug within specified period prior first dose study medication Within 1 month : drug know CYP inducer inhibitor Within 2 week : Prescribed herbal medicine Within 1 week : OTC medicine Within 2 day : Consumption caffeine 5 . A subject participate clinical study within last 2 week 6 . A subject 400mL blood sample ( whole blood donation ) within last 2 week plasma/platelet donation within 1 month .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>